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DOTA = 1,4,7,10 -Tetraazacyclododecane-1,4,7,10-tetraacetic acid
EDC = 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine





HEPES = 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane sulfonic acid )
HPLC = High performance liquid chromatography
NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid
PET = positron emission tomography
RCY = radiochemical yield
RT = room temperature
SOS = start of synthesis
SPECT = single-photon emission computed tomography
TLC = thin layer chromatography
TRAP = 3,3',3''-(((1,4,7-triazonane-1,4,7-
triyl)tris(methylene))tris(hydroxyphosphoryl))tripropanoic acid
TSTU = N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate
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1. Introduction
Positron emission tomography (PET) imaging is widely used and powerful non-invasive
method in the field of nuclear medicine. It is highly sensitive imaging method that is
commonly used in several applications such as oncology, neuroimaging and cardiology. PET
imaging is a valuable tool in medical and diagnosis applications, but also for research
purposes for instance in drug discovery.
In PET imaging process, tracer containing radioactive substance is injected to human body.
PET uses positron emitting radionuclides, such as 11C, 18F, 13N, 15O and 68Ga. 18F has long
been the most used nuclide, but nowadays 68Ga is becoming more relevant due to easy access
from generator and its good radiolabeling properties. When these positron emitting
radionuclides decay, a positron is emitted. As the positively charged positron confronts
negatively charged electron, annihilation process occurs ejecting two 511 keV gamma rays
that can be detected in the PET system.
New techniques for PET imaging are constantly being developed. One major challenge in
PET imaging has been the specific delivery of radioactive compound. Monoclonal
antibodies (mAbs) have long been used as a vector for radionuclide targeting for tumor
detection and imaging. However, antibodies are large molecules that diffuse and transport
slowly in the body. Even though antibodies reach the tumor cell relatively fast, their
complete binding to it can take days due to slow pharmacokinetics. Thus, tracers with longer
half-lives are needed. This leads to poor target to background ratios and to higher activity
doses to healthy cells.
Therefore, a method called pretargeting was invented to solve this problem. In pretargeting
imaging, an unlabeled antibody is first administrated in to body and left lo locate its target
cell such as cancer. After this step, small labeled molecule is injected to locate antibody and
bind to it. Due to its small size, any excess of labeled molecule clears rapidly from blood.
For this reason, pretargeting method provides better target-background ratio and therefore
better images in PET imaging. Several different pretargeting methods have been reported so
far and it has been proven that this approach has brought an excellent contribution to the area
of PET imaging.
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The choice of radionuclide is important as their properties and especially radiolabeling
conditions may differ quite a lot. Radiometals such as 68Ga need a chelating agent to be able
to bind to antibody. As chelating agent’s properties and affinities towards radiometals differ
significantly, it also needs to be chosen carefully. Affinity to radiometal must be high enough
to prevent any metal exchange in human body.
This master’s thesis focuses on development of a synthesis method for HBED-CC-tetrazines,
which are precursors for two new tracer candidates for pretargeted imaging, and on
development of a radiolabeling method for HBED-CC-tetrazines with a positron emitting
68Ga. Chelating agent HBED-CC is used to bind 68Ga forming coordination complex.
Tetrazine part is widely used in pretargeting purposes in fast occurring bioorthogonal click
reactions.
Radiolabeled product [68Ga] Ga-HBED-CC-tetrazine 5b, was tested for different properties,
such as lipophilicity and stability to estimate the compounds suitability as a PET imaging
tracer.
2. Positron emission tomography (PET)
Positron emission tomography, also called PET imaging, is a nuclear medicine imaging
method. It is a powerful method that is commonly used in in vivo biodistribution studies of
molecular probes labelled with radioactive positron emitting nuclide (Phelps et al.,1975).
PET has several applications for example detecting cancer and determining whether the
cancer has spread in the body, brain disorders, heart problems etc. Computed tomography
(CT) and magnetic resonance imaging (MRI) are other commonly used imaging methods
and they can provide excellent structural information about diseased organs. However, they
provide relevant information only when the disease has already altered the anatomy by
chemical changes. PET imaging occurs in a molecular level which makes it an excellent tool
for detecting ongoing disease process.
Most commonly used radiotracers are 11C, 15O, 13N and 18F, among 68Ga. They are all
positron-emitters with relatively short half-lives. Short half-live is needed to minimize the
radiation hazards to the patient. Radionuclide has to be attached to a probe that has the ability
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to bind to a target molecule in patient. The target molecule can be for example a cancer cell
or some other human tissue. Radiolabeled compound is then administrated to the patient
where the compound binds to the target molecule. The distribution of the radiolabeled
compound can then be detected using the imaging process with PET scanner.
PET imaging has a better resolution and sensitivity compared to for example single-photon
emission computes tomography (SPECT) imaging. SPECT imaging is another imaging
method for biomedical applications.
However, PET imaging has also some drawbacks. Compared to CT or MRI, the results with
PET imaging are not so anatomically exact because PET gives information only from the
cells the radioactive molecule has bonded. This means that it can be difficult to localize the
accumulation without a method that can give anatomic information about the exact location.
Therefore, combined imaging modality of PET/CT system is usually used.
2.1. Principle
PET imaging is based on injecting tracer compound labeled with positron emitting
radionuclide and detecting the annihilation coincidence (Zanzonico et al.,2004). When a
positron emitting radionuclide decays, it emits a positively charged particle, a positron. As
positron moves along, it confronts an electron which has a negative charge opposite to
positron. The confront produces annihilation pair consisting two photons travelling to
opposite directions. PET imaging is based on detecting these photons in the scintillator of
the scanning device. The principle of annihilation and detection of the photons is pictured in
figure 1.
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Figure 1. The decay of positron emitting radionuclide and the annihilation process.
PET scanner consists of multiple scintillation detectors around the scanner’s circular shape.
When the photons with an energy of 511 keV smash into the scintillation crystal, they get
absorbed to the crystal lattice generating a light photon as a response (Vallabhajosula et al.,
2009). Produced light photon creates then an electronic pulse in the multiplier. From
multiplier, photons move to amplifier where they get strengthened. After this, electronic
pulse can be detected and processed in a computer.
Detector crystal material can differ in PET systems. Bismuth germinate oxide (BGO),
cerium doped lutetium oxyorthosilicate (LSO) and cerium doped gadolinium
oxyorthosilicate (GSO) have been known to be used in PET detectors (Schöder et al., 2003).
Detector has to have a high stopping power to ensure that all 511 keV photons are noted and
absorbed (Del Guerra et al. 2004). Other requirements for ideal detector are high energy,
spatial and timing resolution.
When detectors are processing the signal from the source, a time interval occurs while an
acceptance of a new signal is not possible (Ziegler,2005). This time interval is called dead-
time loss. During this time the crystal is not able to process a new signal and it will be lost.
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If the counting rate is high, the effect of dead-time loss can affect greatly the amount of
signals achieving the crystal.
The imaging method is based on the detection of the two annihilation photons emitting at
180  °  angle  at  the  same  time  on  opposite  sides  of  the  scanner.  This  process  is  based  on
annihilation coincidence detection (ACD). ACD enables to establish the line of response
(LOR) which assists to locate the source of the annihilation pair in the patient. LOR is a line
between two detectors which displays a possible path of emission. Annihilation pair must
hit the opposite detectors during a time interval of 12-15 ns in order to be considered to be
in coincidence. The annihilation pairs that exceed the time limit fall out of range and are not
detected.
Coincidence events have three different types; a true coincidence, a random coincidence and
a scatter coincidence (figure 2.) (Bolus et al., 2009). A true coincidence happens when two
photons from annihilation exceed the material without interaction and achieve the detectors.
A random coincidence is an event that happens when two photons from different annihilation
processes reach the opposite detectors at the same time. Finally, a scatter coincidence occurs
when one or both of the photons scatter on their way because of interactions with material.
Annihilation radiation can undergo Compton scattering which influences the photons to
change their directions and form coincidences in wrong locations. When scattered photon
travels through material, it loses some of its energy.
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Figure 2. Coincidence events of PET imaging. True coincidence (A), random coincidence (B) and scattered
coincidence (C). Figure is based on an article by Bolus (Bolus et al., 2009).
A random and a scatter coincidence are events that affect a true coincidence and therefore
affect the image of PET scanner by increasing the background in the image. To decrease
detection of false coincidences, some modifications have to take place. Scatter coincidence
photons can be rejected using an energy threshold. Energy threshold is a window that can be
appointed to let through only photons with an energy of 511 keV. Even though the energy
window cuts out major part of scattering photons, some scattering radiation can still pass
through.
As scattered photons are located to wrong LOR they are also removed from the right LOR
when scattering (Lewellen, 2008). This phenomenon called attenuation affects PET image
quality because of the loss of coincidence events. Photons interactions with different
materials in patient can also attenuate the photon as it travels to the detectors. Together these
effects can alter the photons ability to reach the detector within time and energy windows.
To minimize the attenuation, some corrections are in order. Attenuation can be estimated
using CT equipment together with PET. However, usually event though attenuation
corrections are done for the image, still both the corrected and uncorrected images are read.
PET imaging is an excellent imaging method as it is highly sensitive compared to other
imaging modalities. High sensitivity allows smaller tracer amounts which means radioactive
substances can be injected in nano or pico molar quantities. One major potential for PET
imaging is its excellent quantitativity. PET is able to measure the radioactivity that is injected
without emphatically. Quantitative measurement especially with 18F-FDG PET has become
extremely useful tool in diagnosis in the area of oncology.
One of PETs good properties is that it allows the use of short half-life radionuclides. Most
common used nuclides 11C(t1/2 = 20,3 min), 15O(t1/2 = 2,03 min), 13N(t1/2 = 9,97 min), 18F(t1/2
= 109,8 min) and 68Ga(t1/2 = 68 min). This ensures lowest possible radiation doses to patients
going through PET imaging. Most of these elements are found naturally and from human
body. This allows relatively easy substitution mechanisms with element’s stable form.
Biologically stable compounds can also be modified to radiolabeled analogues in a way that
their properties are enhanced for nuclear imaging (Abogye et al., 2003).
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However, there are also some drawbacks in the use of PET imaging. PET system has a
relatively low spatial resolution and it can only image biological disorders at the molecular
level. Therefore, PET systems are usually connected to computed tomography (CT) forming
hybrid PET/CT system. With this combined imaging modality, CT is not used just to acquire
anatomical and functional images but it also corrects the attenuation of the PET data.
Other limitation is the price of PET systems. They can be quite expensive which can be a
restrictive factor in acquisition intensions for research centres. Radionuclides short half-live
can also be a challenging factor in laboratory scale. Radiolabeling conditions and procedures
must be accomplished quickly and readily on-site of the PET imaging,
2.2. Designing a new radiotracer for PET
For a radiotracer to work efficiently as a PET imaging agent, it needs to fulfil several
requirements. Development of a new PET imaging probe demand organic synthesis,
radiolabeling conditions assessment both in vitro and in vivo, and kinetic modeling of the
radiolabeled compound (Li et al., 2010). Molecular imaging probe can be a receptor,
analogue,  protein,  antibody etc.,  as  long  as  it  is  able  to  bind  the  radionuclide  and  form a
stable  compound  or  complex  with  it.  Probe  must  also  handle  physical  conditions  and
different biological reactions, such as metabolism and blood circulation.
Suitable radionuclide is added to the probe in a radiolabeling process. Radiolabeling
procedure must be designed carefully and especially time consumption of the whole process
is a critical step. No more than two times half-life of radionuclide should be spent for the
whole procedure starting from the radiosynthesis and ending in the injection of radiotracer
to patient. Therefore, synthesis must be fast and preferably suitable for automation in
synthesis units. Synthesis should be optimized so that the radiochemical yield is high,
radiochemical purity is sufficient and the specific activity is high enough.
Choice of the probe affects properties of the radiotracer greatly. Radiotracer should have
quite small molecular weight for small molecules can clear from blood circulation faster.
Small compounds also usually provide better target/background ratios. Often probe is chosen
because of biological purposes. Radiotracer might be meant to target certain receptor and
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then probe can be altered to resemble an existing ligand of this receptor. Radiotracers
lipophilicity has also great value to its kinetics.
Another important value to consider with radiotracers is specific activity. Specific activity
is defined by dividing the measured radioactivity per mass or mole of the unlabeled tracer
that was injected (Bonardi et al., 2002). Special activity tells about the ratio of radiolabeled
tracer to the unlabeled probe. Special activity should be high enough to provide good quality
images but also low enough to prevent saturation of detectors. However, each radionuclide
has maximum specific activity that can be calculated from the half-life and mass number of
nuclide (Fowler et al., 2003).
As radiotracer is administrated to human, it must possess favourable pharmacokinetics.
Adsorption, distribution, metabolism and excretion (ADME) are constantly affecting
radiotracer and in order to bind its target, radiotracer has to be modified to endure them.
However, absorption doesn’t have that significant role because radiotracer is usually injected
intravenously. Metabolism of radiotracer should be noted to make sure no harmful or toxic
metabolites are decomposed in body. Formation of radioactive metabolites disturbs the PET
imaging producing background.
3. Pretargeting
Monoclonal antibodies (mAbs) have increasingly been used as an efficient delivery aids for
tumour targeting in imaging and therapeutic applications. Monoclonal antibodies are
antibodies that can be altered to bind to admired substance. Therefore, they have high
binding affinities and an excellent specificity for their target molecule such as different
antigens on the cancer cell membrane. However, due to their big size mAbs tend to have
slow diffusion to tissue and a clearance from blood circulation can take long which often
leads to low target-to-background ratios. Smaller proteins and antibody fragments might
have better clearance but thus their targeting ratio remains lower.
Pretargeting approach was first investigated in 1985 by Reardan et al. The research group
was investigating radiochemistry chelates when they discovered the fact that small metal
chelates could clear from the body a lot faster than bigger antibodies. This finding led to
further studies and the concept of pretargeting was established.
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 Pretargeting method is particularly useful with large mAbs which usually have a slow
tumour accumulation and retention. Pretargeting allows these antibodies to first contact the
tumour cells before injecting the radioactive compound. This way the antibody can achieve
maximum tumour uptake without causing redundant radiation. Pretargeting method allows
the large mAbs to have high tumour affinity but at the same time have the good clearing
properties of a smaller molecule.
Pretargeting concept was first conceived as a method to improve imaging by decreasing the
background activity. Development of pretargeting strategies happened first at the
radioimaging and radiotherapy of cancer area where it is crucial to have good difference
between healthy and cancer cells.
The principle of pretargeting consists of a multi-step process where first the unlabelled
antibody is administrated to localize and bind to the tumour by its anti-tumour binding site.
Antibody is then let to bind to the tumour and the excess of it left to circulate and clear from
the blood. After this step, the small, rapid-clearing radiolabelled compound is then
administered to attach to the sites which the antibody has accumulated. Any excess of small
radiolabeled compound clears rapidly from the body. This radiolabeled compound must have
a high affinity to the antibody. This can be achieved by carefully choosing and modifying
the functionality groups of the antibody. The radiolabelled compound is administrated only
after the antibody has reached its destination and a major part of it has cleared from the blood
circulation. Simplified pattern of pretargeting method is demonstrated in the figure 3.
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Figure 3. The basic idea of a two-step pretargeting method (Knight and Cornelisson, 2014). First the
antibody is administrated to blood circulation following the injection of the radiolabelled compound with
rapid clearance.
The radiolabeled compound is preferred to be small so it reaches the tumour quickly. The
rapid clearance of the compound reduces the radiation exposure outside of the tumour. Small
and fast clearing compound will also bind rapidly to the accumulated antibody and the rest
unbound radiolabeled compound will clear fast from the blood circulation.
There are several different methods for achieving the pretargeting procedure. The original
pretargeting approach was based on the idea of using bispecific antibodies which can bind
to the target antigen as well as the radioactive metal-complex (Stickney et al., 1991). In the
early days, 111In was almost the only nuclide considered, but in further studies other nuclides
have gained more visibility in the area.
However, this method had several drawbacks. The amount of bispecific antibody greatly
affected the tumour uptake. If the injected dose was too low, the uptake remained quite low
(Lollo et al.,1994). Also, if the injection time between bispecific antibody and hapten was
too  long,  the  tumour  uptake  would  also  remain  too  low.  Conversely,  if  the  amount  of
bispecific antibody was too high, and the delay between injections was short, the uptake
would then be reasonable but the radioactive hapten would stay in the blood circulation
elongated. For that reason, the pretargeting method had to be improved.
Another method for pretargeting is to use biotin and (strept) avidin (Hnatowitch et al., 1987).
Avidin is glycosylated and positively charged protein that is found in the egg whites.
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Streptavidin is a bacterial analogue of avidin and it has similar binding properties to biotin.
Biotin is a vitamin which can be found from serum in low concentrations. Biotin has an
extremely high affinity for avidin/streptavidin with a dissociation constant of KD=10-15 M
(Green, 1963). This value exceeds the usual binding constants of antibodies for antigens
which can 10-9 M be at highest (Chang et al., 2002). The bond forms very rapidly and has a
good stability even in very high or low pH values. Biotin-(strept) avidin bond can also persist
different organic solvents and denaturing agents which makes it relatively easy to handle.
First studies in pretargeting exploited this strong binding constant of avidin-biotin. In these
studies, first the biotinylated mAbs was administrated following the radioactive avidin
injection (Paganelli et al., 1988).  Labeled avidin then locates and rapidly binds the biotin
that is attached to the tumour cell. The accumulation of radioactive avidin to biotinylated
mAbs was demonstrated which led to further studies using this high binding pair. However,
there are also some limitations to this method. Usually, radiolabeled streptavidin is injected
after the antibody containing biotin. This may lead to higher activity doses if radiolabeled
streptavidin binds to antibody-biotin compound that is still circulating in blood vascular
system.
In some studies, avidin-antibody was injected first and after that the labeled biotin (Li et al.,
2005). A three-step process was also demonstrated where first biotinylated antibody was
injected, then excess of avidin was added and finally after that the labeled biotin could be
injected. In all these methods, radioactivity in the tumour cell increased. However, injecting
biotin-antibody first has also some disadvantages. Biotin occurs naturally in human cells, so
in case of some tissue containing extra biotin, the background levels may rise too high for
PET imaging.
Complementary oligonucleotides have also shown recently great promise as a pretargeting
method.  Complementary  oligonucleotides,  such  as  DNA  as  well  as  RNA,  can  form  high
affinity interactions with their complementary strands. DNA-DNA conjugation was studied
by Bos  et  al.  (Bos  et  al.,  1994)  in in vitro studies. In this study antibody-complementary
DNA complex is administrated followed by radiolabeled complementary oligonucleotide.
Results showed that this method might be useful for pretargeting purposes due to strong
binding of DNA to antibody and good specific binding of oligonucleotides to cells.
Phosphordiamidate morpholino oligomers (MORFs) have been widely used in order to get
decent signal amplification at  the target (He et  al.,  2004).  In this method, first  the MORF
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conjugated antibody is administrated followed by a complementary MORF attached to
polymer.  Finally, radiolabeled MORF can be injected to locate the antibody in target cell.
This sort of method differs from conventional pretargeting methods by having one extra step
in  the  process.  From  the  use  of  oligomers,  MORFs  have  shown  biggest  potential  in
pretargeting.
The use of complementary oligonucleotides has some advantages comparing to the biotin-
avidin approach. For example, single strand DNA samples that were injected in high
concentrations and continuously did not show significant toxicities.
3.1. Bioorthogonal pretargeting
Bioorthogonal pretargeting reactions have recently gained great interest due to their rapid
and highly selective nature (Van Swieten et al., 2005).  Bioorthogonal pretargeting reactions
use the combination of chemistry and biology. These reactions do not interfere or disturb
biological systems as compounds used in bioorthogonal reactions only bind to those
functional groups of molecules they are intended to. Binding of the molecules happens
covalently which makes the formed product relatively stable. There are some requirements
for the compounds participating in bioorthogonal reactions. Their functional groups must be
modified so that they only interact with each other’s and in vivo studies they should be
nontoxic to the biological system.
These kinds of reactions are nowadays routinely utilized for applications in living systems.
Like  the  pretargeting  method,  bioorthogonal  reactions  also  consist  of  two steps.  First  the
small molecule such as metabolic substrate or enzyme inhibitor attached with a
bioorthogonal function group is administrated to biological system. Once molecule has
reached and bind to its target,
So far, a few different bioorthogonal reactions have been reported, such as the Staudinger
ligation, [3+2] cycloaddition click chemistry reaction between alkynes and azides and [4+2]
Diels-Alder cycloadditions.
Staudinger ligation was one of the first bioorthogonal reactions reported to occur in living
systems (Saxon et al., 2000). Staudinger ligation is based on Staudinger reaction that has
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been widely used in reactions converting azides into amines (Staudinger and Meyer, 1919).
Reaction is based on using azide and phosphine in a production of azaphosphonire which
can then be hydrolysed into amine and very stable phosphine oxide. Staudinger ligation is a
modification of this reaction. Instead of hydrolysing the intermediate azaphosphoire, it is
trapped intramolecularly in a way that it is capable of being stable in aqueous solutions and
not to be hydrolysed. This can be done using ester or other compound containing
electrophilic carbonyl. Reaction takes advantage of selective acylation of α-nitrogen of the
intermediate. Staudinger ligations amide bond formation in aqueous solutions makes it
highly compatible in biological systems. Azide acts as a soft nucleophile when most of the
biological nucleophiles are hard. A simplified reaction of Staudinger ligation in
bioorthogonal chemistry is demonstrated in figure 4.
Figure 4. Simplified bioorthogonal Staudinger ligation between azide and triarylphosphine reagent. Group R
marks for protein, biomolecule etc.
Staudinger ligation was later improved to a reaction called traceless Staudinger ligation. In
this reaction, a cleavable linkage was added to the place of methoxycarbonyl. This method
has been used in synthesis of heterobifunctional linkers for labeling with radiometals (Heldt
et al., 2013). Traceless Staudinger ligation lefts the phosphine oxide as a separate by-product
instead of it being as a part of the final product.
Both traced and traceless Staudinger reactions are highly selective and relatively easy to
proceed. Furthermore, azides are small sized which makes them ideal for pretargeting
purposes. Phosphines however are quite bulky molecules. In traced Staudinger ligation
reactions, phosphine oxide group stays in the molecule. However, this bulkiness can be
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decreased by adding polyethyleneglycol (PEG) chain. This is only necessary if phosphine
group is attached to the labeled molecule that is injected later. If labeled molecule with
phosphine group without addition of hydrophilic group is administrated, binding of the
molecule is not particularly selective towards the target molecule.
Even though Staudinger ligation shoes great promise as a fast and selective reaction, it has
not been proved to operate well in in vivo studies (Vugts et al., 2011). Studies in mice showed
that Staudinger ligation had too slow reaction kinetics for pretargeting purposes. Ligation
was demonstrated to reduce significantly and by-products were observed. Staudinger
ligations slow kinetics remain a problem in in vivo studies.
Recently, click reactions have gained wide interest in the area of biological labelling (Kolb
et al., 2001. Click reactions are fast, high-yielding, relatively simple and they produce
products that are stable at physiological conditions.
One relevant reaction in click chemistry is called strain promoted alkyne-azide cycloaddition
(SPAAC) (figure 5). Its basic principle reaches out to copper catalysed [3+2] azide-alkyne
Huisgen cycloaddition. However, SPAAC reaction can be proceed without copper that can
be harmful when injected to human body. SPAAC reaction involves biomolecule containing
azide which then reacts with certain cyclooctene based probe. SPAAC reaction is highly
efficient in complicated surroundings and in ambient temperatures and it has far better rate
of reaction than Staudinger ligation.
Figure 5. An example of strain promoted alkyne-azide cycloaddition (SPAAC) reaction.
SPAAC reaction has been investigated in vivo for pretargeting approach. Lee et al. reported
SPAAC based bioorthogonal reaction in mice using mesoporous silica nanoparticles (MSNs)
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that were processed with 18F labeled azide compounds for PET imaging (Lee et al, 2013). In
this study SPAAC reaction was accomplished successfully and PET imaging showed good
results of radiotracer being accumulated to tumour location site. Biodistribution experiments
were also tested ex vivo and results showed enhanced tumour-to-blood ratios.
Another bioorthogonal reaction approach using SPAAC reaction was tested using three
different cyclooctene based probes and labeled them with 177Lu (Van den Bosch et al.,2013).
Even though in vitro stability test showed great promise, in vivo studies in healthy mice
showed biodistribution and blood clearance to not be that efficient. These studies showed
that SPAAC reaction has potential for bioorthogonal reactions in pretargeting approach even
though it needs more research.
One recent development in the bioorthogonal chemistry is the use of tetrazines and strained
alkene dienophiles in a reaction called inverse Electron-Demand [4+2] Diels-Alder
(IEDDA) cycloaddition (figure 8). IEDDA reaction was first published in 2008 when
Blackman et al. revealed the reaction between tetrazine(Tz) and trans-cyclooctene(TCO)
forming pyridazines (Blackman et al., 2008). IEDDA is a fast, selective, high-yielding and
clean reaction consisting of two steps. It doesn’t need catalyst and the reaction can occur
also in aqueous conditions. IEDDA reaction has been widely used with radiometals but also
18F is known to be used (Reiner et al., 2014). Copper free IEDDA reaction works relatively
well for metals as well as there is no competition with copper of chelator.
Unlike other bioorthogonal reactions in pretargeting, IEDDA has proved to show great
promise also in in vivo pretargeting studies. Several studies have reported IEDDA based
pretargeting approaches (Rossin et al., 2010, Zeglis et al., 2013, Devaraj et al., 2012). All
these studies report similar approach to the issue. First antibody attached with TCO is
administrated and let to locate its target cell. Then any excess of it is let to slowly clear from
blood circulation. After this small rapidly clearing radiolabeled tetrazine is injected to locate
antibody. When labeled tetrazine locates TCO-antibody, IEDDA reaction occurs fast
followed by clearance of any excess of radioligand. Basic idea of IEDDA bioorthogonal
approach is presented in figure 6.
Chemically IEDDA reaction consists of two steps. First tetrazine and trans-cyclooctene go
through cycloaddition and they produce tricyclic species with a dinitrogen bridge. After this,
dinitrogen is released and dihydropyridazine can be formed as a stable product (Devaraj et
al., 2009).
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Figure 6.  Basic principle of IEDDA reaction of trans-cyclooctene and tetrazine in vivo in pretargeting
approach.
IEDDA reaction between tetrazine-DOTA and trans-cyclooctene-conjugated antibody was
successfully demonstrated in mice for non-invasive imaging (Rossin et al., 2010). This study
managed to establish that a reaction between two separate exogenous compounds can lead
to high-yielding reaction in live mice bearing colon cancer xenografts. Antigen TAG72,
which occurs in variety of cancer cell lines, was chosen for its strong binding properties.
Anti-TAG72 antibody, CC49, was conjugated with TCO and tetrazine was bound to DOTA
chelating agent. Bioorthogonal reaction was demonstrated to occur in vitro with a second
order reaction rate constant of 13,090 ±80 1/Ms. Rapid bioorthogonal reaction was
demonstrated to happen also in in vivo conditions and target to background ratios were
observed to be reasonable.
In another study, 111InTz-DOTA compound and TCO labeled antibody were administrated
to  mice  and  imaged  with  PET  (Zeglis  et  al.,  2013).  This  method  was  proved  to  be  very
efficient in delineating colorectal cancer xenograft in mouse.
Different approach was made by Devaraj et al. as they used dextran derivatives in 18F labeled
polymer-tetrazine compounds (Devaraj et al., 2012). Dextrans are widely used in in vivo
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studies and therefore have suitable reaction kinetics. After modelling of reaction kinetics of
TCO/Tz reaction, research group were able to predict ideal conditions and doses of two
starting materials for in vivo use.
 IEDDA reaction was used in a novel way by research group of Hou et al (Hou et al., 2016).
Instead of using the regular TCO immunoconjugates, they synthesized supramolecular
nanoparticles that were modified with TCO. Supramolecular nanoparticles are excellent for
pretargeting purposes as they are highly small and therefore fast clearing from human body.
Nanoparticles were administrated to tumour carrying mice followed by injection of tetrazine
labeled with 64Cu. This method showed strong PET imaging signals in the tumour area but
also some radioactivity was noticed in liver. This might have been due transchelation of 64Cu
and could be avoided using 18F.
Stability of TCO was greatly improved in in vivo conditions after a discovery that
isomerization of trans-cyclooctene into unreactive cis-cyclooctene (CCO) deactivates TCO
(Rossin et al., 2013). Isomerization was noted to happen because of interactions with copper-
containing proteins. The issue was solved by inducing steric hindrance in the TCO molecule.
The research group also discovered that TCO derivatives substituted with in axial position
showed higher reactivity compared to equatorial positions. This lead to a much more stable
and reactive compound as well as better tumour-to-non-tumour ratios. This was
demonstrated in 111In radiolabeling studies, where the radioactivity of tumour didn’t show
significant changes even after three days. This indicates for an extremely stable compound
in in vivo conditions.
3.1.1. Tetrazine
Tetrazine has been widely used in bioorthogonal cycloaddition reactions in live cell labeling.
Tetrazine ligations used in bioorthogonal reactions were first presented in 2008 in IEDDA
reactions (Blackman et al., 2008). Basic structure of tetrazine compound is presented in
figure 7. This basic structure consists of six-membered aromatic ring containing four
nitrogen atoms although structure is often modified with different molecules since mere
tetrazine is highly unstable.
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Figure 7. Structure of 1, 2, 4, 5-tetrazine.
In this master’s thesis work, we used two different tetrazine derivatives with PEG4 link and
an amine at the end of the link. The structures of tetrazine-PEG4-amines are presented in
figure 8. Tetrazine compounds solubility to aqueous solutions is significantly improved by
a hydrophilic polyethylene glycol PEG4 link. PEG link also decreases steric hindrance and
reduces aggregation.
Figure 8. Structures of tetrazine-PEG4-amine 1a and methyltetrazine-PEG4-amine 1b.
Tetrazine compounds are known to be very reactive as dienes and therefore react rapidly and
efficiently in IEDDA reactions (Boger et al., 1983). Tetrazines can react with a wide range
of dienophiles or pyridazines forming only dinitrogen N2 as a by-product.
Tetrazine has been widely used together with trans-cyclooctene (TCO) analogues mostly in
IEDDA reactions (Maggi et al. 2016). Reaction between tetrazine and TCO happens
extremely fast with a reaction rate of 210-30000L mol-1 s-1 (Devaraj et al., 2009) which
23
makes it extremely suitable for bioorthogonal reactions. Reaction of TCO and tetrazine is
presented in figure 9.
Figure 9. Reaction of TCO and tetrazine has an extremely high rate of reaction.
Chelating agent has to be used in order to use radiometal 68Ga as an imaging agent in
tetrazine structures. Because of 68Ga coordination chemistry, it cannot bind directly to
tetrazine. Pentetic acid (DTPA) have been used as an example as chelating agent with
tetrazine (Nichols et al., 2014).  In this work, amide bond is formed between the amine group
of tetrazine-PEG4-amine and the carboxylic acid group of HBED-CC.
4. Gallium-68
Interest for 68Ga radiopharmaceuticals in basic and in clinical study has increased rapidly
over the past few years. 68Ga has multiple advantages comparing to other radionuclides used
in PET studies. 68Ga is a positron emitter which decays with a half-life of 67, 7 minutes and
it emits a high-energy positron (E= 1899 keV). It decays 89 % by positron emission and 11%
via electron capture. Short half-life makes it compatible with pharmacokinetics of most of
the low molecular weight radiopharmaceuticals such as peptides and antibody fragments.
68Ga can be produced on site using 68Ge/68Ga-generator which makes it a viable option in
comparison to the cyclotron-based PET isotopes such as 18F. The parent nuclide, 68Ge has a
long half-life of 270 days, which ensures the cost-effective availability of 68Ga. Together
with simple and short radiolabeling procedures, 68Ga is a viable option for PET imaging.
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4.1. Production of 68Ga
As 68Ga can be produced by 68Ge/68Ga-generator, it doesn´t need on site cyclotron (Fani et
al. 2008). The parent nuclide, 68Ge decays with a half-life of 270.8 d by electron capture.
The relatively long half-life of 68Ge  combined  with  the  half-life  of 68Ga makes this pair
nearly perfect for the generator system as the long half-life of 68Ge allows the generator to
have long a shelf-life. Consequently, the 68Ge/68Ga-generator can also be eluted several
times a day for experiments.
The production of 68Ge is demonstrated in the figure 10.
Figure 10. Production of 68Ge by (p, 2n) reaction from 69Ge.
The first 68Ga producing generators were eluted using EDTA so that the eluent could be
directly used as a [68Ga] Ga-EDTA complex. However, since the complex was already
formed, it did not leave room for the development of other 68Ga complexes. Complex
decomposition would have reduced the overall yield and been too time-consuming.
Generators were then developed to produce the 68Ga as hydrated ionic form, 68Ga3+.
Different sorbent materials from metal containing Al2O3 or ZrO2 to a bit better sorbent CeO2
were tried but the yield of 68Ga remained  too  low.  Nowadays,  the  most  common sorbent
materials in generators are TiO2 and SnO2 for these kinds of generators provide good yields.
68Ga must be separated from its parent nuclide 68Ge to be used in coordination chemistry as
ionic from. 68Ge/68Ga-generators operation is based on thin layer chromatography. The
stationary phase is titanium dioxide in which the parent radionuclide 68Ge is adsorbed. 68Ge













SnO2. The mobile phase is a solvent able to elute 68Ga from the system. The column is then
placed inside a lead shield from where plastic eluate and eluent lines are provided. 68Ga can
be eluted from the column by ultrapure 0.1 M HCl using a syringe. The injection of HCl into
the generator must be done carefully. Injection flow should be around 2 ml/min to avoid any
extra pressure in the system. Air bubbles during the injection of the solvent must be avoided
for they can also disturb the column.
68Ge breakthrough from the generator must be eliminated for successful 68Ga radiolabeling.
Any usage of different metals must be avoided in elution of generator and possible metal
impurities must be washed off from the generator.
4.2. 68Ga coordination chemistry
Gallium has  an  electron  configuration  of  [Ar]  4s2 3d10 4p1 which means it belongs to the
group 3 in the periodic table. 68Ga occurs mainly in the +3-oxidation state in aqueous
solutions, due to its low redox potential. However, the free Ga3+ ion is only stable in acidic
conditions. With higher pH, hydrolysis appears forming insoluble Ga(OH)3. As the pH rises,
gallium exits predominantly as gallate ion, Ga (OH)4- making it soluble in physiological pH
(Green and Welch, 1989). However, the total solubility of gallium in physiological pH has
a reliance on the specific activity of the compound.
The Ga3+ ion is classified as a hard acid, which means it will make thermodynamically stable
complexes with highly ionic hard base ligand donors, such as hydroxamate, amine,
phosphonate and carboxylic acids (Pearson, 1963). Therefore, gallium’s chelate chemistry
is being consisted of ligands containing nitrogen or oxygen donor atoms. Gallium’s general
coordination chemistry is very similar to transferrin, which occurs in physiological fluids
(Bartholoma et al. 2012). Transferrin is a blood plasma glycoprotein containing Fe3+, which
has a lot of same properties as Ga3+ ion. Both ions have almost the same ionic radii (62 pm
for Ga3+ and 65 pm for Fe3+) and a lot of similarities in their coordination chemistry with a
same major coordination number six. Therefore, especially the similarities in the
coordination chemistry must be taken noticed in the preparation of gallium
radiopharmaceuticals.
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Ga (III)  can form complexes with cyclic and open chain structures of polydentate ligands
(Decristoforo et al. 2012). Ga (III) can form four-, five- and six-coordinated complexes but
the six-coordinated complex is the most stable one.
4.3. Radiolabeling with 68Ga
The radiolabeling with 68Ga has to be performed in a pH range 3-4.5 (Nayak and Brechbiel,
2009).  The  adjustment  of  pH  must  be  done  rapidly  after  the  elution  of  the  generator  to
achieve efficient radiolabeling.
Different conditions for 68Ga labeling of DOTA were attempted by Mokaleng et. al (2014).
Labeling procedure included three different temperatures (room temperature, 60 °C and 100
°C) and different time intervals of 5-45 minutes. Labeling done in room temperature leaded
to maximum 40 % labeling efficiency regardless of labeling time. With higher temperature
60 °C, labeling efficiency rose up to 83 %. Labeling time didn’t seem to have much of an
effect. With highest temperature of 100 °C, they were able to rise the labeling efficiency to
96 %. Labeling efficiency was demonstrated to vary between 86 to 93 % depending on
labeling time. Effect of pH was also tested and the optimum was founded in between pH of
3-3.5.
4.4. Chelators for 68Ga labeling
Since gallium can form insoluble hydroxide, Ga(OH)3, in water at physiological pH, direct
radiolabeling of peptides or other similar compounds is almost impossible. For that reason,
chelating  agents  are  commonly  used  in  order  to  stabilize  gallium.  Chelators  must  be
kinetically inert in the pH 4-8 in clinical use so ligand transfer doesn’t occur with transferrin
protein. If ligand transfer with transferrin would happen, metal retention to liver and lung
would be inevitable. Other properties for good chelator are ability to form peptide bond and
also good solvent solubility.
Chelating agents are compounds that contain one or more ligands, which means they donate
a  lone  pair  of  electrons  in  order  to  form a  bond with  metal  ion.  Almost  all  the  chelating
agents coordinate Ga with hexadentate structure, corresponding to gallium’s six-coordinated
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complex being the most stable one, although some chelators with coordination number four
or five have been reported. Chelators must have multiple oxygen donor atoms and amines in
order to bond 68Ga strongly in pseudo-octahedral geometry. Most of the chelators are
bifunctional, which means the chelator, that is complexing 68Ga, can also bind to the target
biomolecule for example antibody or peptide with a suitable functional group. Bifunctional
chelator must fulfill two requirements; it should be kinetically stable so the bond between
metal and chelate doesn’t break even in the presence of other serum cations such as Ca2+,
Mg2+ or Zn2+ and also the chelation to metal should occur fast and efficiently due to the short
half-live of Ga68.
Desferrioxamine-B (DFO) was one of the first used chelators for radiolabeling studies with
68Ga. It has been widely used in labeling with high radiochemical yield (Mathias et al., 1996).
DFO binds gallium rapidly and with an excellent radiochemical yield. DFO consists of three
hydroxamate groups that are available for coordination with Ga3+ (Figure 11). It also has free
amine groups that can bind to biomolecules which makes it a bifunctional chelator. However,
DFO can only bind metals in high concentration to ensure acceptable radiochemical yield
(Caraco et al., 1998). When DFO was used in nanomolar amounts, Ga3+ coordination was
not that effective and yield were noticed to be too low.
The most used chelator for radiolabelling with 68Ga is currently the aminocarboxylate
macrocycle DOTA, although also smaller NOTA is constantly used for its extremely stable
complex with 68Ga (Ray Banerjee et al., 2016). Recently, the triazacyclononane-phosphinate
(TRAP) has also shown excellent binding ability for 68Ga (Notni et al. 2011). The structures
of DFO, DOTA, NOTA and TRAP are presented in the figure 11.
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Figure 11. Structures of DOTA, NOTA and TRAP chelating agents for Ga68.
DOTA  chelator  has  been  widely  used  in  radiolabeling  with 68Ga  for  its  structure  and
properties as a chelating reagent. DOTA radiolabeling with 68Ga requires high temperatures
from 90°C to 100 °C and relatively long incubation times (Wadas et al., 2010). This is
because the ring distortion determinates the reaction conditions. Compared to NOTA
structure, DOTA has an extra carboxylic acid after complex formation which doesn’t affect
its properties as a bifunctional chelator.
DOTA’s bioconjugate DOTANOC is a somatostatin analogue used clinically as a
somatostatin receptor PET tracer. DOTA bioconjugates have shown to have high stability in
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serum. Although the 68Ga-DOTA complex has a high kinetic stability, it also has several
disadvantages. The radiolabelling process requires a high temperature and quite long
radiolabelling time. Typical radiolabelling conditions necessitate heating to 95 degrees for
up to 30 minutes at pH below 5 (Heppeler et al.1999). High temperature as well as the low
pH aren’t suitable for proteins which might be used in molecular imaging. Also, the long
radiolabelling time allows 68Ga to decay.
NOTA chelators have shown great stability and fast incorpotation of 68Ga. Labeling process
can happen in lower temperatures than with DOTA (Blom et al., 2011).
TRAP ligand is a NOTA derivative with a high efficient 68Ga3+ complexation (Notni et al.,
2010).  TRAP complex with 68Ga possesses a high thermodynamic stability with a value of
logK = 26,24. Radiolabeling is reported to succeed in lower pH than usually with other 68Ga
chelators (Šimeček et al., 2012). Formation of 68Ga-TRAP complex occurred even in very
acidic conditions with a pH as low as 1 meaning that 68Ga eluate could be used straight from
generator after elution with 0.1 M HCl.
Three different phosphinate ligands methylphosphinic (TRAP-H),
methyl(phenyl)phosphinic (TRAP-Ph) and methyl(hydroxymethyl)phosphinic acid (TRAP-
OH) as well as comparative 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) were
labeled with 68Ga and the stability of these compounds were tested by using potentiometry
(Notni et al., 2012a). Thus, all TRAP ligands were found to stay stable in both acidic and
alkaline conditions. Complex formation with 68Ga was reported to happen faster than with
conventional chelators such as DOTA derivatives. Labeling was also able to occur within a
wide range of pH starting even from pH<2.
Same research group studied TRAP chelators labeling properties when attached to peptides
(Notni et al., 2012b). TRAP-, NOTA- and DOTA-peptides were compared and reported
from their specific activity. TRAP-peptide was observed to be able to form complex with
68Ga  with  a  much  lower  precursor  amount  (1  nmol)  than  NOTA-  or  DOTA-peptides.
Radiolabeling process was observed to be highly efficient which permits the process to be
possible for kit labeling procedure.
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4.4.1. HBED-CC
Since 68Ga chemistry and it´s use in the PET imaging have been a rising topic in the research,
new chelators for the radiolabelling with 68Ga has been developed. One of these chelators is
HBED-CC, which is a bifunctional chelator showing great promise in the radiolabelling
studies with 68Ga.  The structure of HBED-CC is demonstrated in the figure 12.
Figure 12. The structure of bifunctional chelator HBED-CC, which is used in the radiolabelling with 68Ga.
HBED-CC consists of four carboxylic acids and two hydroxyl groups. Together with
nitrogen, they form hexadentate complex with 68Ga. Rapid 68Ga complex formation with
HBED-CC is allowed because of its acyclic structure (Eder et al. 2008). HBED-CC complex
formation doesn’t interfere with its bifunctionality as one carboxylic group does not
participate in the 68Ga-HBED-CC complex.
Compared to several other 68Ga chelators, HBED-CC does not require a large amount of
precursor for the radiolabeling to occur with a high yield. In a study of Eder et al. (2008)
only 0.11 mg of HBED-CC-antibody (mAb425) complex was needed for an 89 %
radiochemical yield with a specific activity of 37 GBq/µmol.
The properties of HBED-CC in the radiolabeling with 68Ga were investigated in a research
by Eder et al. (2012) where they compared the [68Ga] HBED-CC to DOTA complexes. They
discovered that even though the lipophilicity of the DOTA complex is higher than HBED-
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CC’s, the structure of the molecule is crucial for better binding properties. HBED-CC’s
structure has an optimal aromatic feature because of the hydrophobic interactions.
Prostate-specific membrane antigen (PSMA) is a cell surface protein which PSMA is
expressed normally in brains, kidney and prostate. Over-expression in prostate refers to
prostate cancer. HBED-CC have been widely used as a chelator with Glu-urea-Lys(Ahx)
PSMA inhibitor and it has been studied to be very good candidate for clinical applications
of prostate cancer imaging (Eder et al., 2014).
HBED-CC can form diastereomers as it is forming coordination complex. This is due to the
chirality of nitrogen atoms in its structure. However, it has been studied that the formation
of diastereomers can be controlled (Eder et al., 2014). Applying different temperatures in
the radiolabeling process, thermodynamically most stable diastereomer can be guided to
form. When the radiolabeling was made in room temperature, it resulted in 50 % of another
diastereomer to be formed. However, when sample was let to stay in room temperature in
pH 4 for couple of hours, stereomer ratio quickly turned to thermodynamically more stable
one. It was demonstrated that small amounts of less stable diastereomer in the sample did
not significantly affect the binding properties of [68Ga] Ga-PSMA-HBED-CC to PSMA.
5. Coupling reagents for amide bond formation
Coupling reaction between two starting materials HBED-CC and tetrazine-PEG4-amine
was done by amide bond formation. Amide bond also known as peptide bond is a strong
covalent bond that usually occurs between two amino acids in a peptide chain (Abdelmoty
et al.1994).
To achieve the amide bond between carboxyl group and amino group, coupling reagent is to
be introduced to the reaction. In this work, three different coupling reagents, TSTU, HATU
and EDC, were used to compare their investment to the reaction. Each of the coupling
reagents structure is presented in figure 13.
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Figure 13. Coupling reagents used in the amide bond formation reaction.
All coupling reagents form the amide bond with the same principle (Montalbetti and
Falque, 2005). The reaction consists of two steps, the activation of the carboxyl group and
the acylation of the amino group. First step is the activation of carboxylic moiety. This step
is usually the critical one and in order for it to work all other carboxylic acid groups need
be protected to keep the reaction in control. If this step occurs too slowly, the next step
might not happen due to coupling reagents degradation (Al-Warhi et al., 2012). In the
second step, other compounds such as amino acids amine acts a nucleophile and attacks the
activated carboxylic acid to form the amide bond. This step requires energy which explains
why reacting carboxylic acid must be activated.
However, all three coupling reagents have little different properties and therefore the effect
on the peptide formation reaction might differ (Han and Kim, 2004). TSTU is usually used
in aqueous solutions. Formation of by-products must be taken noticed when working with
TSTU. HATU is an aminium-based coupling reagent that is widely used for its good reaction
yields and rates. It reacts rapidly producing very little side reactions and by-products.
However, excess use of HATU can lead to unwanted reaction with unprotected N-terminal.
EDC is a carbodiimide that is commonly used in the peptide modifying reactions. EDC can
produce urea based side-product which can be disposed in the workup process.
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Reaction with HATU usually happens in two steps. First HATU reacts with carboxylic acid
forming the OAt activated ester. Then the activated ester reacts with amine the group. The
reaction mechanism for the coupling reaction using HATU as a coupling reagent is presented
in a figure 14.
Figure 14. Reaction mechanism of coupling reaction with HATU.
Reaction starts as the base DIPEA deprotonates the carboxylic acid of HBED-CC. As a
result, carboxylate anion forms and attacks the electron deficient carbon atom of HATU as
seen in the figure 13. Derived carboxylic acid intermediate becomes activated and the
formed HOAt anion can react with it in order to form OAt activated ester. After this, OAt
activated ester reacts with tetrazine amine and the amide bond can form.
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6. Aim of the study
The aim of this study was to develop tetrazine based compound labeled with 68Ga that
would have the possibility to cross the cell membrane. Ability to cross the cell membrane
as well as the blood-brain-barrier can happen by passive diffusion, where the lipophilicity
of a molecule plays a significant role. To achieve this aim, tetrazine was coupled with
chelating agent HBED-CC so the labeling with 68Ga could be possible. Coupling reaction
as well as radiolabeling of the compound with 68Ga was optimized with different
conditions including different temperatures, reaction times and coupling reagents. The
complete synthesis route is presented in figure 15.
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Figure 15. The synthesis route of the product. Reagents and conditions: a) HATU, DIPEA, DMF, 48 h, RT,




7.1.1. Methods and instruments for analysis of the synthesis products
7.1.1.1. High-performance liquid chromatography (HPLC)
High-performance liquid chromatography (HPLC) was used for the purification of the
product. HPLC is a technique that can be used for identification, quantification and
purification of compounds. It is a type of liquid chromatography that uses high pressure for
maximizing high speed and performance. Principle of HPLC relies on the mixture sample
being divided into separated components based on its physical and chemical properties such
as polarity, charge and molecular weight. HPLC consists of pumps, injector, column,
detector and the computer data station. HPLC instrument is presented in figure 16.
Figure 16. Simplified HPLC system.
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The purpose of the pumps is to force liquid and the sample with it through the column and
the whole system. Pressure in the system can alter plenty depending on the column size and
flow rate. A typical pump can however reach pressure up to 500-600 bar. Pumps can function
in isocratic or gradient mode. Isocratic pump keeps the mobile phase composition constant
as the gradient pump can deliver multiple solvents and vary the mobile phase composition
during the chromatogram.
Sample is injected to HPLC using an injector. Sample must be liquid and in a small volume.
Injection can happen manually or automatically using an autosampler. Volume of the sample
depends on the size of the column. From the injector, sample travels with continuously
flowing mobile phase into the HPLC column.
Column is probably the most important part of the HPLC system. It contains the stationary
phase in which the absorption of components takes place. Choice of the column is important
in both analysis and purification processes.  HPLC can be used as normal phase HPLC or
reversed phase HPLC. In normal phase HPLC, stationary phase is polar and the mobile phase
non-polar, such as hexane, chloroform or diethyl ether. Using this column type, more polar
samples tend to stay in the polar surface of the stationary phase. Reversed phase HPLC is
more commonly used method. In this method, stationary phase is nonpolar and mobile phase
is more polar such as acetonitrile or water. This way compounds that are more polar tend to
move with mobile phase and therefore have smaller retention times.
Detector is located at the end of the HPLC system and its purpose is to detect the analytes
as they elute from the column. HPLC system can use a lot of different detectors depending
on the examinee compound and its features. One of the most common detectors is ultraviolet-
visible spectroscopic (UV/VIS) detector which uses compounds ability to show absorption
spectrum of ultraviolet or visible light.
In this work, Shimadzu LC-solution equipment was used with CBM-20A control unit and
LC-20AD pump. During the radiosynthesis, Canberra radiation detector was attached to the
LC-system. Spectrums were analysed with a LC-solutions computer program.
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7.1.1.2. Mass spectrometry (MS) and nuclear magnetic resonance (NMR)
For analysing the product, mass spectrometry (ESI-MS) and nuclear magnetic resonance
(NMR) were used.
Mass spectrometry is a technique used to identify, detect and quantitate different compounds
and molecules based on their mass-to-charge (m/z) ratio (Ho et al.,2003). MS instrument
consists of ion source, mass analyser and detector. Mass spectrometers work by converting
molecules of the analyte into charged ions using a certain ionisation process (De Hoffmann
and  Stroobant,  2007).  ESI-MS  uses  electrospray  ionisation  source  which  uses  a  strong
electric field to form an aerosol from the liquid sample. The liquid which contains the sample
is  passed  through  a  capillary  tube  with  a  continuous  stream  that  is  generated  by  a  high
voltage. This high electric field induces a charge to pile up at the end of capillary tube
causing the liquid to form little droplets with high charge. Because of N2 gas flow or rising
temperature in the system, droplets size decreases as the solvent in them evaporates. This
leads to a surface charge density to increase and for the droplet radius to decrease. Finally,
sample ions in the droplet are ready to desorb from the surface and continue to mass analyser
to get analysed (Fenn et al. 1989). From the results, graph is given with corresponding peaks.
The  most  intensive  peak  is  assigned  with  abundance  of  100  %  and  all  the  other  peaks
abundances are given as percentages of the biggest peak. In this work, a Bruker Daltonics
microTOF-Q I (Bruker Daltonics, Bremen, Germany) was used and the data was analysed
with DataAnalysis 3.2 software.
NMR is a commonly used technique for determining the structure of an organic compound
Bottomley, 1982). It advances magnetic properties of a certain atomic nuclei. The basic
principle is that when magnetic nuclei is introduced into magnetic field, it will settle in a
certain way with specific number of orientations (Gunther, 2013). Subatomic atoms, such as
electrons, protons and neutrons have a spin. With some atoms, these spins are paired and
cancelled by each other’s, but others, such as 1H and 13C the nucleus corresponds to overall
spin. When atom confronts electric field, atom can transfer energy from basic energy level
to higher energy level. This energy transfer corresponds to certain frequency that is the same
frequency that energy is emitted when spin returns to its basic level. As the signal match,
this transfer is measured and processed into a NMR spectrum. In this work, the NMR spectra
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were recorded with Varian 300 MHz spectrometer and analyzed using the SpinWorks 2.4.2.
software.
7.1.1.3. Autoradiography
Autoradiography was used in the determining of the radiochemical purity of the labeled
compound. Autoradiography is technique to image radioactive emissions on a surface of an
imaging plate. Photosensitive plate absorbs the radiation from radioactive sample and stores
it on the plate that can later be read using a certain scanner. Plate consists of photo-stimulable
phosphor that is coated on a polyester support layer (Johnston, 1990). Phosphor layer is
usually bariumfluorobromide with a trace amount of bivalent europium (BaFBr:Eu2+). In the
process, europium excites from ground state as Eu2+ to excited state as Eu3+ . When plates
are scanned with laser, excited BaFBr:Eu2+ crystals release energy as a blue light before
returning to ground state. Blue light is collected in the system and image can be formed to
computer. Autoradiography method is sensitive, relatively fast and has an excellent
resolution. In this work, we used FLA-5100 scanner and Image Reader FLA-5000 Series V
1.0 computer program. Image was later processed with Aida Image Analyzer V 4.0 program.
Autoradiography was used to read to the TLC plates during the radiolabeling process.
Radio-thin-layer-chromatography (TLC) scanner was used in determining of radiolabeling
yields. Radio-TLC is a technique for analysing radiochemical purity from thin layer
chromatography (TLC). With this technique, TLC is placed on the machine and the system
proceeds the TLC providing a graph. High energy collimator and a bismuth germanate
(BGO) detector  are  usually  used  for  PET isotopes.   In  this  work,  Scan-RAM Radio-TLC
detector (Lablogic) was used for the measuring and Laura software was used for analysing.
7.1.2. 68Ge/ 68Ga-generator
68Ge/68Ga-generators operation is based on column chromatography. The stationary phase
is titanium dioxide in which the parent radionuclide 68Ge is adsorbed. 68Ge absorbs firmly
to different solid supports, for example metal oxides such as Al2O3, TiO2 and SnO2. The
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mobile phase is a solvent able to elute 68Ga from the system. The column is then placed
inside a lead shield from where plastic eluate and eluent lines are provided.
68Ge/68Ga-generator was Eckert-Ziegler model (batch HHGE01) with an original activity
of 1850 MBq in 7.9.2015. For one elution generator could give approximately 200 MBq of
68Ga per 10 millilitres of ultrapure 0.1 M HCl.
7.1.3. Chemicals
Starting materials, coupling reagents and other solutions are presented in table 1.































Acetonitrile, (ACN) CH3CN VWR
Deuterated Methanol CD3OD C.E. Saclay
Dichloromethane, (DCM) CH2Cl2 Fisher Chemical
Dimethylfomamide, (DMF) C3H7NO Sigma-Aldrich
Dipropylethylamine, (DIPEA) C8H19N Sigma-Aldrich
Ethyl acetate C4H8O2 Sigma-Aldrich
n-Hexane C6H14 Merck
Methanol, (MeOH) CH3OH Sigma-Aldrich
Tetrahydrofuran, (THF) C4H8O Sigma-Aldrich
Trifluoroacetic acid, (TFA) C2HF3O2 Fisher Chemical
Two  buffers  were  used  in  the  process.  HEPES  buffer  (1.5  M,  pH  7,5)  was  used  in
radiolabeling procedure and phosphate buffer (20 mM, pH 7.0) in the lipophilicity
determination process. Both buffers were made in laboratory.
20 mM phosphate buffer was prepared by measuring 1.7 g of Na2HPO4 and 1.2 g of
NaH2PO4*2H2O and diluting to 1000 ml of water. After that pH was adjusted to 7.0 with
NaOH.
1,5 M HEPES buffer was prepared by measuring 35.7 g of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid and diluting it to 100 ml of milliQ-water. After that, pH was
adjusted to 7.5 using concentrated NaOH.
TLC solvent used for analysis of the intermediates and the final product was prepared from
ethyl acetate and hexane in a ratio of 1:2.
Fe-solution for the iron challenge was prepared by measuring 0.14 g of Fe(III)NO3 and
diluting it to 5 ml of purified water to obtain 27 mg/ml iron solution.
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7.2.  Methods
7.2.1. Synthesis of the precursor for radiolabeling
Synthesis of HBED-CC-tetrazines 3a and 3b are presented in figure 17.





HBED-CC-tris(t-Bu)-ester 2 (50 mg, 0.071 mmol, 1.3 eq) was dissolved in 0.45 ml of DMF
and added to a 100 ml flask. HATU (58 mg, 0.15 mmol, 2.8 eq) was added to the reaction
flask with 0.35 ml DMF and the mixture was let  to stir  for 10 minutes in dark and under
argon atmosphere. Tetrazine 1a (25 mg, 0.053 mmol, 1 eq) was first dissolved in 0.6 ml
DMF and then added to the reaction mixture carefully using a syringe and a needle. The
reaction mixture was then let to stir for 20 minutes in dark and under argon atmosphere.
Finally, DIPEA (33 µl, 0.19 mmol, 3.5 eq) was added to the mixture and the reaction mixture
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was  let  to  stir  for  48  hours  in  room  temperature,  covered  from  light  and  under  argon
atmosphere. The progress of the reaction was followed by TLC every 24 hours during the
reaction. Ethyl acetate: hexane (1:2) solution was used in the silica TLC as a solvent. Rf(3a)
=0.46.
Extractions were made to change and remove the solvent. First, 10 ml of ethyl acetate was
added to the reaction mixture. Extractions were made six times using liquid-liquid
extraction. First 5 ml of purified water was added to reaction mixture and the separation
funnel was shaken gently. Pink product stayed in the upper level at the organic solvent. When
two layers clearly separated, the lower aqueous layer was drained into a beaker. After that,
the  same procedure  was  repeated  five  times  with  5  ml  of  5% LiCl.  After  extractions,  the
organic layer was dried using MgSO4, filtrated and evaporated to dryness using rotavapor.
TLC was made to make sure the product stayed with the right layer during extractions. Ethyl
acetate: hexane (1:2) solution was used in the silica TLC as a solvent. The final product was
purified with high-performance liquid chromatography. HPLC device and parameters are
presented in table 2. Yield: 44 mg (75 %) as a pink solid. Purity > 95%.
1H NMR (300 MHz, CD3CD): δ 1.39-1.48 (27H, 1.39 (s), 1.39 (s), 1.39 (s)), δ 2.00 (2H,
tt, J = 5 Hz), δ 2.44 (6H, t), δ 2.76-2.88 (8H, t), δ 3.02 (4H, t, J = 3 Hz), δ 3.20 (2H, t, J = 7
Hz), δ 3.42 (2H, t, J = 5 Hz), δ 3.60 (2H, s ; 2H, s), δ 3.61-3.77 (16H, 3.64 (t, J = 4 Hz), 3.64
(t, J = 3 Hz), 3.65 (t, J = 4 Hz), 3.64 (t, J = 4 Hz), 3.65 (t, J = 3 Hz), 3.64 (t, J = 4 Hz), 3.67
(s), 3.71 (t, J = 6 Hz)), δ 4.53 (2H, s), δ 6.69 (1H, dd, J = 9, 1 Hz), δ 6.89 (4H, dd), δ 7.00
(1H, dd, J = 2, 1 Hz), δ 7.56 (2H, ddd, J = 8.0, 2.2, 0.4 Hz), δ 7.98 (2H, ddd, J = 8, 2, 1 Hz),
δ 8.49 (1H, s).
ESI-MS[M+H]+ m/z calculated 1117.6107 for C58H84N8O14+, found  1117.6332.
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HBED-CC-tris(t-Bu)-ester 2 (59 mg, 0.084 mmol, 1.5 eq) was dissolved in 0.5 ml of DMF
and added to a 100 ml flask. HATU (60 mg, 0.16 mmol, 2.8 eq) was added to the reaction
flask with 0.3 ml DMF and the mixture was let to stir for 10 minutes in dark and under argon
atmosphere. Tetrazine 1b (25 mg, 0.056 mmol, 1 eq) was first dissolved in 1 ml DMF and
then added to the reaction mixture carefully using a syringe and a needle. The reaction
mixture was then let to stir for 20 minutes in dark and under argon atmosphere. Finally,
DIPEA (34 µl, 0.20 mmol, 3.5 eq) was added to the mixture and the reaction mixture was
let to stir for 48 hours in room temperature, covered from light and under argon atmosphere.
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The progress of the reaction was followed by TLC every 24 hours during the reaction. Ethyl
acetate: hexane (1:2) solution was used in the silica TLC as a solvent. Rf(3b) = 0.38
After that, 10 ml of ethyl acetate was added to the reaction mixture. Extractions were made
six times using liquid-liquid extraction. First 5 ml of purified water was added to reaction
mixture and the separation funnel was shaken gently. Pink product stayed in the upper level
at the organic solvent. When two layers clearly separated, the lower aqueous layer was
drained into a beaker. After that, the same procedure was repeated five times with 5 ml of
5% NaCl. After extractions, the organic layer was dried using MgSO4, filtrated and
evaporated to dryness using rotavapor. TLC was made to make sure the product stayed with
the right layer during extractions. Ethyl acetate: hexane (1:2) solution was used in the silica
TLC as a solvent. The final product was purified with high-performance liquid
chromatography. HPLC device and parameters are presented in table 2. Yield: 47 mg (76 %)
as a pink solid. Purity > 95%.
1H-NMR (300 MHz, CD3CD): δ 1.35 (27H, s), δ 2.55 (9H, t), δ  2.83-2.90 (4H, 2.75 (t, J =
4.4 Hz), 2.79 (t, J = 4.4 Hz), (4H, 2.86 (t, J = 6.8 Hz), 2.86 (t, J = 7.4 Hz)), δ 3.08 (4H, t, J =
2.7 Hz), δ 3.17 (2H, t, J = 6.8 Hz), δ 3.30 (2H, t, J = 4.8 Hz), 3.57-3.74 (3.57  (2H, s), 3.59
(2H, s), 3.64(16H, t, J = 4.2 Hz), δ 4.53 (2H, s), δ 7.57 ((2H, ddd, J = 7.8, 1.5, 0.4 Hz), (1H,
dd, J = 8.5, 0.4 Hz), (4H, 6.85 (dd, J = 8.5, 2.4 Hz), (dd, J = 8.5, 2.4 Hz), (dd, J = 8.5, 0.4
Hz), (dd, J = 2.4, 0.4 Hz)), (1H, dd, J = 2.4, 0.4 Hz), δ 8.51 (2H, ddd, J = 7.8, 1.6, 0.4 Hz),
δ 10.34 (H, -OH).
ESI-MS[M+H]+ m/z calculated 1131.6342 for C59H87N8O14+, found 1131.6661.
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7.2.1.1. Deprotection reaction
Deprotection reaction of HBED-CC-tetrazine to form deprotected compound 4b is
presented in figure 18.





Purified product 4b (3 mg, 0.0027 mmol) was weighted and added to a flask. DCM (4 ml)
and TFA (1 ml, 0.013 mmol)) were combined in a small flask and then added to the reaction
mixture. After addition, reaction was let to stir in room temperature for 24 hours. Para film
and folio were used around the flask to avoid evaporation and light exposure.
After 24 hours, reaction was stopped and TLC was made to make sure the reaction was
completed. TLC silica plate was first let to run in 1:1 ethyl acetate: hexane solvent and then
dipped in ethanol solution of bromocresol green. Rf(4b) = 0.72. Yield(4b) = 1.5 mg (60 %)
as a pink oil. Purity > 99 %.
1H NMR (300 MHz, CD3CD): δ 1.96 (2H, tt, J = 7, 5 Hz), δ 2.43 (9H, t), δ 2.74 (6H, t), δ
2.97 ((4H, t, J=5 Hz)), (4H, t, J = 7 Hz), (4H,t, J = 3 Hz)), δ 3.44 (2H, t, J = 4.8 Hz), δ 3.96
(16H, t), δ  6.98 (1H, dd, J = 8.5, 2.4 Hz). The tetrazine peaks are not visible in the
spectrum.
ESI-MS[M+H]+ m/z calculated 963.4464 for C47H63N8O14, found 963.4198.
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7.2.2. Radiosynthesis of 68Ga
Deprotected product 4b was labeled with 68Ga (figure 19).





The 68Ge/68Ga- generator was first eluted with 0, 1 M ultrapure HCl-solution to achieve
68Ga-solution as 68Ga3+-  ion.  Elution  volume  was  10  ml  and  an  average  activity  in  that
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amount was 200 MBq. After the addition of 68Ga solution (300 µl, 6 MBq, at SOS) to vial
containing 4b (0.5 mg) dissolved in 200 µl of 1.5 M HEPES (pH=7.5), the pH of the labelling
solution  was  adjusted  to  4  with  1  M HCl  (about  40  µl).  When the  pH was  adjusted,  and
checked with pH paper, the samples were left to incubate in 85° for 20 minutes. After
incubation, the radiolabelling yield was determined using radio-HPLC and TLC. The solvent
used for TLC was 10 mM PBS with pH=7.4. The TLC was then analysed with TLC scanner.
For the radio-HPLC, water and MeOH solvents were used. Conditions for HPLC are
presented in table 3. 5b: Radiochemical yield (DCY): 96 %, radiochemical purity: >98 %
(TLC), 96 % (HPLC).
Table 3. HPLC parameters for determining radiolabeling yield from the reaction mixture and radiochemical






      - Length
      - Inner diameter
      - Particle size
















7.2.3. Determining the lipophilicity
The lipophilicity of the compound 5b was determined using a shake flask method. The
distribution  coefficient  of  the  product  was  measured  between  1-octanol  and  20  mM
phosphate  buffer  in  pH = 7.4.  First,  same amount  (5  ml)  of  both  solvents  were  added  to
centrifuge tube. Then 200 µl of the radiolabelled product was added and the activity of the
content was measured using a carpenter dosimeter. The tube was then shaken vigorously for
1-2 minutes before moving the content of the tube to extraction funnel. The phases were then
let to separate for 10 minutes. The activities of the organic and aqueous phase were then
determined with the carpenter dosimeter as well as with a gamma counter. The logP value
can be calculated from equation
ܲ݃݋݈ = ݃݋݈ ௌ௢௟௨௧௘೚೎೟ೌ೙೚೗
ௌ௢௟௨௧௘ೢೌ೟೐ೝ
(1)
The P value (partition coefficient) is a ratio between compounds concentration in octanol
divided by compounds concentration in water. However, with radioactive substances,
radioactivity concentration is used as a parameter instead of concentration.
7.2.4. The Fe challenge experiment and the stability of the product 5b
For Fe-challenge, two samples were prepared. First sample was used as a control containing
200 µl 1.5 M HEPES buffer (pH 7.5), 100 µl of the radiolabelled product 5b and 100 µl 0.1
M  HCl.  The  other  sample  contained  200  µl  1.5  M  HEPES  (pH  7.5),  100  µl  of  the
radiolabelled product 5b and 100 µl of FeNO3-solution (27 mg/ml of Fe (III)). The samples
were stored in +37° and measured during different intervals with a radio-HPLC as well as
with a radio-TLC (Whattman paper). The times intervals used were 0h, 1h, 2h, 3h, 4h and
6h. For TLC, 100% MeOH was used as a solvent.
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8. Results and discussion
8.1. Optimizing the synthesis of the precursor for radiolabeling
The synthesis of the HBED-CC-tetrazine-PEG4 was made from two starting reagents,
HBED-CC chelating reagent and tetrazine-PEG4-amine (1a and 1b) (figure 20). Reaction
conditions, choice of the coupling reagent and method of purification were all tested to get
the optimum yield from the precursor synthesis.  Two different tetrazines (1a and 1b) were
used in the synthesis. Molecular masses of the obtained products were 1117 g/mol for 3a
and 1131 g/mol for 3b. Coupling reaction between HBED-CC and tetrazine-PEG4-amine
(1a) was attempted with three different coupling reagents, TSTU, HATU and EDC. When
best coupling reagent was chosen, also methyltetrazine-PEG4-amine (1b)  was  used  as  a
starting material.
Figure 20. Coupling reaction of HBED-CC and tetrazine-PEG4-amine (1a and 1b).
Coupling reaction between HBED-CC and tetrazine-PEG4-amine was first attempted with
coupling reagent TSTU. Reaction time varied from 12 hours to 24 hours. However, with that
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reaction, the desired product was not obtained. This was stated when a sample taken after
extractions was measured by a mass spectrometry (figure 21).
Figure 21. MS spectrum of the coupling reaction using coupling reagent TSTU. The desired product 3a (1117
g/mol) cannot be seen in the spectrum.
From the MS spectrum can be seen that product with a molecular mass of 1117 g/mol cannot
be seen. In contrast, multiple smaller peaks appear among the HBED-CC starting material
(MW= 700 g/mol) which refers that the desired reaction did not occur.
After unsuccessful reaction with TSTU, another coupling reagent, HATU, was tested.
Reaction succeeded with a yield of 60 % after 24 hours’ reaction time. Reaction time was
prolonged to 48 hours which lead to better yield of 72 %. However, another coupling reagent
was still tried to get better yield with a shorter reaction time.
Next reaction was attempted with EDC. Reaction time was 48 hours which resulted to a yield
of 72 % before purification. However, in this reaction the obtained product turned from pink
to brown during the following night. Product was injected to HPLC where multiple peaks
were seen which indicated that the product had decomposed. This might have been due to
wrong storage conditions (in room temperature) or the EDC might have been from an old
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batch. However, as HATU had given relatively good results, no further experiments were
done using EDC.
Based on these results, reaction was to be continued using HATU as a coupling reagent.
Coupling reaction was repeated several times using different conditions with reaction yields
varying from 65 % to 85 %. Reaction time varied from 8 hours to 96 hours, but the maximum
yield was achieved with 48-hour reaction time in room temperature. Reaction was also
performed in higher temperature, in 85 °C. Reaction yield turned out to be quite good, almost
75 %.  However, it was chosen not to use higher temperature in future experiments because
the reaction was easier to perform in room temperature and the yield didn’t differ that much.
Still, it was significant to see that reaction in 85 °C could also work, because radiolabeling
with 68Ga occurs in that temperature. Reaction was finally optimized to 48 hours in room
temperature which resulted to yield of 82 ± 4 %.
The obtained product was purified using two different methods. Silica column
chromatography and High Performance Liquid Chromatogram (HPLC) were both used and
compared to achieve the best recovery of the product. From these two methods, HPLC was
chosen as a better purification technique. HPLC was faster, easier and it leaded to a better
recovery of the product.
However, silica column chromatography was also tested. Before purification, the product
was first dissolved in 6 ml of ethyl acetate. After that, the reaction mixture was divided into
two parts so the purification could be done in smaller batches to maximize the yield. One
batch  contained  approximately  10  mg  of  the  product.  Both  items  solvents  were  then
evaporated with rotavapor for the purification. Purification was made using silica which is a
polar absorbent. That means that the more polar compounds tend to stay with the stationary
phase while the nonpolar compounds travel through the column faster. Before starting the
purification, the column was first prepared with 10 ml of ethyl acetate.
When the column had been prepared accordingly, the elution of the product could be started.
First 10 ml of hexane was added to the column carefully using funnel so the surface of the
silica didn’t get disturbed while the liquid was being poured. The flow rate of the solvent
was adjusted using air pump. Five 2 ml fractions were collected into small tubes. When the
solvent level was almost at the surface of the silica, 10 ml of 1:1 ethyl acetate: hexane-
solution was added. After five 2 ml fractions were collected, 10 ml of ethyl acetate was
added to the column and fractions were again collected. Finally, the column was washed
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with 10 ml of EtOH to make sure that every compound had passed through the silica column.
To verify the right fraction with the product, TLC was made with a small drop from every
test tube. A small drop from pure sample of the product was also placed to the TLC plate
alongside other drops. The TLC plate was then sprayed with ninhydrin, heated and the
appeared marks were compared with the mark of the standard to recognise the right fractions.
Silica column purification turned out to be very slow and not that effective of a method. For
that  reason,  HPLC  was  chosen  as  a  purification  method.  Even  though,  also  the  HPLC
purification took quite a long time due to columns ability to handle only small batches. Also,
the product had to be purified two times to get pure product. Reason for second purification
was the residue of the starting material, HBED-CC shown in the mass spectrometry
spectrum. The HPLC picture of pure product (3b) is shown in a figure 22. Retention time
was observed to be 8.6 minutes for 3b and 8.5 minutes for 3a.
Figure 22. Purified product (3b) injected to HPLC. Retention time of the product was 8, 7 minutes. Retention
time for 3a did not differ significantly (8.5 minutes). UV/VIS detector was used with a wavenumber of 254
nm. Retention time of HBED-CC was 7,5 minutes and tetrazine was 2,9 minutes.
Purified products 3a and 3b were characterized with MS and NMR. Pictures of MS-spectrum
and 1H NMR spectrum are in the appendix 1 and 2 for 3a and in appendix 3 and 4 for 3b.
Deprotection reaction was made after the product (3b) was discovered to be purified.
Deprotection reaction was made to remove the protecting tert-butyl-groups so the
radiolabeling with 68Ga would be possible and the coordination complex could be formed.
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In the deprotection reaction, only TFA was used as an acid for the deprotection of tert-butyl-
groups. The reaction time, however, was altered couple of times. Deprotection of the starting
material, HBED-CC, was used in the optimizing of the reaction time. Reaction time was first
only  4  hours,  but  the  reaction  didn’t  complete  during  this  time.  Reaction  time  was  then
increased to 12 hours and finally to 24 hours, which was demonstrated to be optimal reaction
time. Reactions progress was monitored with a TLC using bromocresol as a dying agent.
Bromocresol can be used to reveal compounds with functional groups whose pKa is below
5. Deprotected carboxylic groups appear on the silica plate as yellow spots on a green
background.
Deprotected product was characterized with MS and NMR. Pictures of MS and 1H NMR
spectrums are in the appendix 5 and 6 for 4b. However, the 1H NMR characterization of the
obtained deprotected product 4b was not successful. 1H NMR spectrum does not show peaks
around 6-9 ppm where the chemical shifts of tetrazines benzene rings hydrogens should be
(figure 23).
Figure 23. Zoom up of the 1H NMR spectrum of deprotected product 4b around 6-9 ppm where the peaks for
tetrazines benzene rings hydrogens 1a, 1b and 2a, 2b should be seen.
56
This might indicate that the bond between tetrazine and HBED-CC was broken down in the
deprotection reaction with TFA although this is not likely due to the extremely strong amide
bond between them. Decomposition of the molecule from some other part might still be
possible. Still, MS spectrum shows the right mass of 963 g/mol for the product 4b (appendix
5). Reason for bad quality of NMR spectrum could be the too small amount of sample for
such a large molecule. For the same reason, 13C NMR spectrums could not be measured.
However, without proper characterization data, the right structure of the molecule cannot be
guaranteed.
8.2. Radiolabeling with 68Ga
Radiolabeling with 68Ga was first tested with deprotected HBED-CC. In this experiment,
two different temperatures were used and the incubation time was also altered. Samples were
incubated in room temperature and in 85 ºC, and the incubation time was altered from 5
minutes to 20 minutes. The best yield was gained with an incubation time of 20 minutes.
Expectedly, the radiolabeling yield turned out to be very high, 97.9 % with the sample
incubated in 85 ºC and 95.8% for the sample in room temperature.  HBED-CC labeled with
68Ga was then injected to radio-HPLC and the retention time turned out to be 6.4 minutes.
These conditions were then used in the radiolabeling process of the actual product 4b.
For the product 4b, the radiolabeling procedure was repeated several times using different
amounts of the product. Amounts of precursor, obtained radiochemical yield and calculated
specific activity are presented in table 4.
Table 4. The amount of precursor 4b used in the radiolabeling and product yield and specific activity. Spesific
activity is calculated by dividing the starting activity by substance amount (Bq/mol).





The starting activity varied from 5-5,8 MBq. To ensure the radiochemical purity, TLC was
made from the product 5b alongside free 68GaCl3 from generator and the TLC paper was
57
scanned with autoradiography. [68Ga] Ga-HBED-CC-tetrazine (5b) got carried from the
starting line with eluent and no free 68GaCl3 was left in the application level. Thus, the
radiochemical purity for [68Ga]Ga-HBED-CC-tetrazine (5b) got defined with a value of 98.2
% (figure 24).
Figure 24. TLC made from spots of [68Ga] Ga-HBED-CC-tetrazine (5b) and free 68GaCl3 from generator. The
eluent used for TLC was 10 mM PBS with pH=7.4.  Obtained product 5b can be seen in area of 40-50 mm as
a big peak in spectrum 1.
After incubation time, complex formation was done and obtained labeled product 5b was
injected to radio-HPLC (figure 25).
Figure 25. Radio-HPLC chromatogram of labeled product 5b. 50 µl, 0,4 MBq was injected. Two peaks appear
with retention times 6.7 and 7.5 minutes. A possible peak for labeled starting material HBED-CC can be seen
with a retention time on 6.4 minutes.
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Two  peaks  with  retention  time  of  6.7  and  7.5  minutes  appear.  Retention  time  of  labeled
HBED-CC was 6.4 minutes and a small  peak with that retention time can be seen in this
spectrum also. This means that there might have been a small residue of unreacted HBED-
CC in the sample. However, the amount of that residue seems to be insignificant.
To make sure product was completely labeled, 68GaCl3 (V= 10 µl,  A= 0.2 MBq) straight
from generator was injected to HPLC to determinate its retention time. As expected,
hydrophilic 68GaCl3 eluted from HPLC rapidly with a retention time of 2.6 minutes.
Chromatogram of radio-HPLC of 68GaCl3 is presented in figure 26.
Figure 26. Radio-HPLC chromatogram of 68GaCl3 injected to HPLC. Free 68GaCl3 retention time is 2.7
minutes.
Two peaks appearing in the spectrum (figure 25) could be isomers caused of HBED-CC
structures complex formation with 68Ga. Possible isomers are presented in figure 27.
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Figure 27. Possible isomers of the radiolabeled product 5b.
As can be seen from the picture, 68Ga can form coordination complex with the product either
from  one  of  the  carboxylic  acids  or  from  amine  group.  Isomers  of  HBED-CC  were
investigated in a study by Eder et al. (2014). Isomer formation did not seem to affect
radiolabeling procedure. However, it was stated that exact chemical nature of these
complexes needed to be investigated more thoroughly to clarify more of their biological
properties. Thus, when it comes to injecting this possible radiotracer to human body, isomer
formation might affect the binding properties.
8.3. Determining the lipophilicity
The lipophilicity experiment was first tested with free 68Ga  in  0.1  M  HCl  solution.  As
expected, 68GaCl3 turned out to be hydrophilic with a value of -1.59. The lipophilicity of the
product was determined three times to achieve the average and standard deviation of the
results. The results from each experiment are combined in a table 5.
Table 5. Results from lipophilicity test of 5b.
Experiment A(organic) A(aqueous) logP
1 0.068 0.832 -1.08
2 0.039 0.745 -1.28
3 0.042 1.25 -1.47
Average logP value of the product 5b turned out be below zero with a value of – 1.28 ± 0.19.
This means that the product is hydrophilic. For pretargeting purposes, low lipophilicity is
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usually admirable for tetrazine to achieve maximum specific binding in in vivo conditions.
During the experiment, lipophilicity of 68Ga-DOTA-tetrazine complex was also determined.
LogP value turned out to be even smaller with a value of -1.45.
Lipophilicity can be defined as the affinity of a molecule to a lipophilic environment. Low
logP value corresponds to low lipophilicity. Low lipophilicity is admirable for downplaying
nonspecific binding and to prevent redundant radioactivity for intestinal and liver as it makes
the positioning of radiation source more difficult. The determination of logP value is
especially important for a radiotracer, because lipophilicity rate affects greatly absorption,
distribution, metabolism and excretion (ADME) of the compound in human body. Usually,
very hydrophilic compounds are soluble in water and they have functional groups that can
form ions.  This leads the compound to clear rapidly through kidneys and to be unable to
cross the blood-brain-barrier (Jolliet-Riant et al., 1999). For that reason, lipophilicity
determinations are especially important in brain studies.
8.4. The Fe challenge experiment and the stability of the product 5b
The iron challenge experiment as well as the stability test were performed in parallel during
the same day. The radiolabelled product was challenged with Fe, to estimate the stability of
the product in solution with excess Fe.  The Fe solution was about 10 times more molar than
the product 5b molarity corresponding to the molarity of iron circulating in human body
Experiments for the iron challenge and the stability of the product were performed at  the
same time. For the first 3 hours’ compound remained quite stable. Labeling percentages for
product with and without iron from hours 3 to 6 are presented in the table 6.
Table 6. Labeling percentages after 3-6 hours with and without iron.
Hours from labeling Without Fe With Fe
3 80 % 44 %
4 75 % 45 %
6 69 % 48 %
During this experiment, labeling with 68Ga did give a labeling percentage of only 83 %.
This might explain why compound seem to become so unstable after 3 hours. However,
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iron seems to have some effect on 68Ga-product complex. This is something that should be
investigated in the future for a radiotracer should be able to resist Fe exchange in the
complex.
Eder et al. (2008) did a stability test for [68Ga]HBED-CC-mAb425 conjugate in human
serum for 4 hours at 37 ºC. The results showed that human serum did not affect the
stability of the conjugate. Therefore, it is important to renew the stability test in human
serum instead of using buffer.
The same research group did also a stability test for 68Ga-labeled peptides using an excess
of apo-transferrin (Eder et al. 2012). After 2 hours of incubation in 37 ºC, 68Ga was still
associated with the peptide. This indicates that the HBED-CC complex should be able to
withstand iron.
9. Conclusions and future work
Synthesis of HBED-CC-tetrazine-PEG4-amine was successfully optimized with suitable
conditions.  Reaction  was  done  several  times  with  reasonably  high  yield  of  82  ±  4  %.
However, the reaction time of the coupling reaction with HATU is relatively long and the
shortening of this reaction time might be relevant in the future. There was some trouble with
the purification of product. Purification process had to be done two, sometimes even three
times to obtain pure product. This might have been because starting material HBED-CC had
similar retention time than the product and therefore was hard to separate. Changing the
HPLC method or column might have helped with the problem.  Optimization of deprotection
reaction was also successfully done with starting material HBED-CC. However, with the
product 4b characterization with NMR was not completely done which leaves the complete
structure of compound unclear. Fortunately, MS spectrum gave the right mass, so we could
move to the radiolabeling part with 68Ga. However, NMR spectrums from the deprotected
product 4b need to be done in the future.
Radiolabeling of the product 4b gave a good yield of 97 % and radiochemical purity turned
out to be over 98 %.  The possible isomer formation of HBED-CC is something to keep in
mind to, as it has been reported also before. Luckily, two isomers didn’t seem to affect the
radiolabeling in any harmful way. However, as said before, if this kind of compound was to
be injected to human patient, it should be investigated more thoroughly.
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Iron challenge experiment and the stability test did not give promising results. However, like
said before, radiolabeling occurred in the first place with a smaller radiochemical yield than
what was usually obtained. There are several studies to achieve before product can be tested
in vivo. The stability of product still needs some further investigations as the experiment in
this  master’s  thesis  was  done  in  buffer  solution.  Stability  tests  should  be  done  in  human
serum instead of buffers to get more significant results. Iron challenge experiment however
should be tested again with a better radiolabeling yield in the beginning. For the future, it is
also better to do the challenge of the complex of nanoparticles/HBED-CC-tetrazine with free
HBED-CC. Iron exchange in complex is crucial to determinate if radiotracer development
is to be continued. In future, in vivo biodistribution studies are required to resolve
compounds behaviour in human body and do determinate its suitability as PET imaging
tracer.
Past several years have shown rapid development in the pretargeting approach and especially
in the bioorthogonal chemistry mainly because of fast kinetics of click chemistry reactions
and tetrazine bioorthogonal reactions. HBED-CC-tetrazine complex radiolabelled with 68Ga
brings an interesting and valuable addition to the area of PET imaging nuclear medicine.
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11. Appendix
Appendix 1. MS-spectrum of tert-butyl protected HBED-CC-tetrazine-PEG4-amine (3a).
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Appendix 2. 1H-NMR-spectrum of tert-butyl protected HBED-CC-tetrazine-PEG4-amine
(3a).
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Appendix 3. MS-spectrum of tert-butyl protected HBED-CC-tetrazine-PEG4-amine with
methyl group (3b).
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Appendix 4. 1H NMR-spectrum of tert-butyl protected HBED-CC-tetrazine-PEG4-amine
with methyl group (3b).
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Appendix 5.MS-spectrum of deprotected HBED-CC-tetrazine-PEG4 with methyl (4b).
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Appendix 6. 1H NMR-spectrum of deprotected HBED-CC-tetrazine-PEG4-amine with
methyl group (4b).
